A
Aumet
The largest B2B Healthcare solution that supports companies with their business decisions & performance.At Aumet, we aim to help manufacturers, distributors and healthcare providers to exchange data…
About Aumet
Aumet operates a business-to-business healthcare technology platform, initially established in the United States in 2016 and now headquartered in Saudi Arabia. The company was founded by a team including Yahya Aqel, who serves as CEO, Mohammad Issa, Jamal Abu Samra, and Shahed Jaber. Aqel's background as a biomedical engineer with extensive entrepreneurial experience in the medical supplies industry was foundational to the company's creation. This venture followed previous entrepreneurial efforts by the co-founders, including Issa's experience in launching three prior startups.
Read full description
The firm’s business centers on a digital marketplace that connects pharmaceutical manufacturers, distributors, and healthcare providers, with a primary focus on pharmacies. Operating in key markets such as Saudi Arabia, Jordan, and Egypt, Aumet serves a network of over 10,000 pharmacies. The platform is engineered to streamline procurement, enabling healthcare providers to aggregate bulk orders for better pricing and manage inventory efficiently. Aumet generates revenue through its comprehensive platform that facilitates transactions and data exchange within the healthcare supply chain.
Aumet's core product is an AI-enabled platform featuring the "Aumet Marketplace" mobile application and an integrated enterprise resource planning (ERP) system. This digital marketplace allows pharmacists to order medicines, cosmetics, and medical supplies directly from a wide array of distributors. Key functionalities include predictive analytics for forecasting procurement needs, which helps pharmacies optimize stock levels and reduce costs. The system also provides auto-inventory management with real-time ERP integration, automated stock replenishment, and multiple payment options, thereby digitizing the entire ordering and payment cycle. Since its inception, Aumet has secured significant funding, including a $7 million Pre-Series A round, to enhance its AI capabilities and expand its market reach.
Latest news
Press, funding announcements and product moves mentioning Aumet.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2026 | $12M | $48M | Right Side Capital Management · Shorooq · AAIC Investment · Qatar Development Bank | ↗ |
| SEED✓Equity / VC | Mar 2023 | $7M | $28M | AAIC Investment · Shorooq | ↗ |
Growth signals
Latest recorded traffic for Aumet is 39K monthly website visits, down 11.4% over the last three months. Aumet's team grew 3.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
AAIC Investment
Shorooq
Series A6 investors entered at this stage
Emkan Capital
Right Side Capital Management
Qatar Development Bank
Cigalah group
Salehiya Healthcare
SABAH.fund
Other known investors6 additional known investors
Core Vision InvestmentsFaisal Al-Abdulsalam
Riyadh Techstars Accelerator
Stryde71
Tasmu Smart Qatar
Techstars
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aumet on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aumet’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.





